Summary of Key Information:
Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026 (Q2 FY27)
Nature of Filing / Announcement: Regulatory filing pursuant to SEBI LODR Regulations 30 and 33
Date of Board Meeting / Approval: October 16, 2026 (Meeting time: 12:30 PM to 1:20 PM)
Audit Opinion: Unmodified conclusion issued by Deloitte Haskins & Sells LLP for the limited review.
Auditor’s Comment: The review report states that nothing has come to their attention that causes them to believe the statement contains any material misstatement. The consolidated results include financial information of 2 subsidiaries not reviewed by their auditors, but these are considered not material to the Group.
Key Financial Highlights [Unit: ₹ Crores]
Consolidated Results:
Revenue from Operations:
- Q2 FY27: ₹417.34 (33.1% YoY increase from Q2 FY26: ₹313.54)
- H1 FY27: ₹798.94 (26.3% YoY increase from H1 FY26: ₹632.69)
Total Income (Revenue + Other Income):
- Q2 FY27: ₹417.88
- H1 FY27: ₹802.17
Net Profit:
- Q2 FY27: ₹28.46 (Significant improvement from Net Loss of ₹10.10 in Q2 FY26)
- H1 FY27: ₹44.77 (Significant improvement from Net Profit of ₹0.42 in H1 FY26)
- Attributable entirely to equity shareholders of the Company.
EPS (not annualized for quarters, Face Value ₹10):
- Basic & Diluted for Q2 FY27: ₹5.92
- Basic & Diluted for H1 FY27: ₹9.49
EBITDA (if available): Not explicitly disclosed in the provided data.
Other Equity (excluding Non-controlling interests): ₹1,387.93 as of September 30, 2026 (Audited: ₹1,208.37 as of March 31, 2026)
Cash and Cash Equivalents: ₹24.11 as of September 30, 2026 (Audited: ₹4.48 as of March 31, 2026)
Debt:
- Non-current Borrowings: ₹177.50
- Current Borrowings: ₹392.10
- Total Borrowings: ₹569.60
Standalone Results:
Revenue from Operations:
- Q2 FY27: ₹417.34
- H1 FY27: ₹798.94
Net Profit:
- Q2 FY27: ₹29.61
- H1 FY27: ₹46.60
EPS (not annualized for quarters, Face Value ₹10):
- Basic & Diluted for Q2 FY27: ₹6.16
- Basic & Diluted for H1 FY27: ₹9.87
Other Equity: ₹1,392.40 as of September 30, 2026 (Audited: ₹1,210.93 as of March 31, 2026)
Cash and Cash Equivalents: ₹23.90 as of September 30, 2026 (Audited: ₹4.00 as of March 31, 2026)
Debt:
- Non-current Borrowings: ₹137.29
- Current Borrowings: ₹383.22
- Total Borrowings: ₹520.51
Segment-wise Performance:
The Group's operations relate to only one reportable segment: Active Pharmaceutical Ingredient (API). Accordingly, no separate segment disclosure is provided.
Corporate Actions:
Dividend: Not Specified
Rights Issue: The company has raised ₹446.62 crores out of a total rights issue size of ₹449.95 crores as of September 30, 2026. The proceeds are held in bank accounts pending deployment as per the Letter of Offer.
Other Significant Information:
Exceptional Items: A loss of ₹4.50 crores was recorded in Q2 and H1 FY27 on the sale of Capital work in progress relating to the Vizag plant, which has been mothballed since FY 2023-24.
Accumulated Losses:
- Consolidated: ₹274.16 crores as of September 30, 2026 (March 31, 2026: ₹319.33 crores)
- Standalone: ₹272.53 crores as of September 30, 2026 (March 31, 2026: ₹319.53 crores)